Though the topics are complex, it is a hallmark of the MEDICA LABMED FORUM that all presentations are short, to the point and easy to understand, and can be addressed in further depth in panel discussions.
Like last year, the sophisticated programme was organised by Prof. Stefan Holdenrieder and Prof. Georg Hoffmann (German Heart Centre at the Technical University of Munich). During each lunch break, exhibiting companies at MEDICA 2023 are given the opportunity to introduce themselves with short presentations about their company.
On Monday, 13 November, MEDICA starts with two “scandalous” issues which currently cause heated debates throughout the field of laboratory medicine: the potential threat to the existence of small IVD companies and specialised labs posed by the “In-Vitro Diagnostics Regulation” (IVDR) and the use of artificial intelligence (AI) with new possibilities and also risks. Led by Prof. Astrid Petersmann (University of Oldenburg), in the morning there will be a professional discussion concerning the challenges posed by the new EU directive for the quality assurance of diagnostic tests, and how these can be overcome. In the afternoon, an equally stimulating discussion will follow, concerning how artificial intelligence and machine learning are about to change the way we work in laboratories. One of the most advanced application areas currently is the automatic evaluation of microscopic images and complex data sets, for example in the diagnosis of leukaemia.
Advances in clinical diagnostics
On the second day, led by Prof. Stefan Holdenrieder, German Heart Centre Munich, there will be a discussion of new developments in laboratory medicine within the fields of oncology and cardiology. Over the past several years, research has revealed the enormous potential of blood examinations for the diagnosis, prognostication and therapy management of different types of cancer. For example, circulating tumour cells and nucleic acids are becoming established as a second methodological pillar, which opens up new perspectives beyond the classic examination of tissue for the field of oncology.
A change of perspective is visible in cardiology as well: Molecular diagnostic tests allow for the increasing improvement of risk assessment for arteriosclerotic cardiovascular diseases, and thanks to advances in heart surgery, the importance of genetic examinations in the case of congenital heart defects is also on the rise. Other than that, thromboinflammation presents a new pathophysiological concept for understanding thrombogenesis.